Last reviewed · How we verify
Rilzabrutinib dose 1
At a glance
| Generic name | Rilzabrutinib dose 1 |
|---|---|
| Also known as | SAR444671 |
| Sponsor | Sanofi |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease (PHASE2)
- A Study of Rilzabrutinib in Adult Patients With Immune Thrombocytopenia (ITP) (PHASE2)
- Food Effect and Relative Bioavailability Study of Rilzabrutinib in Healthy Participants (PHASE1)
- A Food Effect and Relative Bioavailability Study of Rilzabrutinib in Healthy Participants (PHASE1)
- Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis (PHASE2)
- A Study to Evaluate the Effect of Mild and Moderate Hepatic Impairment on the Single-Dose Pharmacokinetics of Rilzabrutinib (PRN1008) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rilzabrutinib dose 1 CI brief — competitive landscape report
- Rilzabrutinib dose 1 updates RSS · CI watch RSS
- Sanofi portfolio CI